|
시장보고서
상품코드
2008054
선천성 고인슐린혈증 치료 시장 : 질환 유형별, 약제 유형별, 투여 경로별, 유통 채널별, 지역별Congenital Hyperinsulinism Treatment Market, By Disease Type, By Drug Type, By Route of Administration, By Distribution Channel, By Geography |
||||||
선천성 고인슐린혈증 치료 시장은 2026년에 1억 5,840만 달러로 추정되고 있으며, 2033년까지 3억 2,160만 달러에 달할 것으로 예상되고 있습니다. 2026-2033년에는 CAGR 8.2%로 성장할 것으로 전망되고 있습니다.
| 리포트 범위 | 리포트 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 1억 5,840만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 2026-2033년의 예측 기간 CAGR : | 8.20% | 2033년 시장 규모 예측 : | 3억 2,160만 달러 |
선천성 고인슐린혈증(CHI)은 고인슐린혈증성 저혈당이라고도 하며, 저혈당을 유발하는 희귀한 내분비 질환입니다. 주로 신생아, 영아, 소아에게 발병하여 영구적인 뇌 손상을 유발하고, 중증 저혈당의 가장 빈번한 원인으로 꼽힙니다. 췌장 베타세포에 의한 인슐린 과다 분비는 KATP 채널 유전자(ABCC8, KCNJ11, HNF4A, HNF1A, HADH, UCP2)의 유전자 변이 또는 GLUD1, GCK, SLC16A1의 활성화 변이를 일으켜 선천성 고인슐린혈증을 유발합니다. 선천성 고인슐린혈증(CHI)은 영구적인 뇌손상의 위험이 높기 때문에 간질, 뇌성마비, 신경발달장애 등의 합병증을 예방하기 위해 빠른 진단과 즉각적인 치료가 필요합니다. 미국 희귀질환기구(NORD) 데이터베이스에 따르면 대부분의 국가에서 약 25,000-50,000명당 1명꼴로 CHI가 출생하며, 대부분 생후 1개월 이내에 저혈당이 발생합니다. 불쾌감, 졸음, 과도한 공복감, 빈맥은 흔한 증상이지만, 발작이나 혼수상태와 같은 더 심각한 증상이 나타날 수도 있습니다. 선천성 고인슐린혈증은 다양한 병형이 있으며, 그 원인도 다양합니다. 예를 들어 일시적인 유형도 있고, 유전적 결함으로 인해 평생 지속되는 유형도 있습니다. 미숙아는 인슐린 과다 분비로 인해 저혈당이 발생할 수 있습니다. 이러한 부적절한 인슐린 분비의 원인은 아직 명확하지 않지만, 며칠에서 몇 달 동안 지속될 수 있습니다.
시장 역학
Zealand Pharma A/S, 한미약품, Eli Lilly and Company 등 주요 기업이 선천성 고인슐린혈증 치료를 위한 새로운 치료법을 지속적으로 개발하고 있는 것이 예측 기간 중 글로벌 선천성 고인슐린혈증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 선천성 고인슐린혈증 치료제 시장의 성장을 촉진할 것으로 예상됩니다. 예를 들어 2019년 5월, 생명공학 기업 Zealand Pharma A/S는 다시글루카곤의 임상 3상 시험을 시작했습니다. 이 임상시험은 선천성 고인슐린혈증 소아환자에 대한 다시글루카곤의 유효성과 안전성을 평가하는 것을 목적으로 하고 있습니다. 본 시험은 2022년 12월까지 완료될 예정입니다. '다시 글루카곤'은 글루카곤의 펩티드 유사체로, 7개의 아미노산 치환을 통해 피브릴 형성 및 펩티드 응집을 제거하도록 설계된 펩티드 유사체입니다.
본 시험의 주요 특징.
- 이 보고서는 세계 선천성 고인슐린혈증 치료제 시장에 대한 상세한 분석을 제공하며, 2021년을 기준연도로 하여 예측 기간(2022-2030년) 시장 규모와 연평균 성장률(CAGR%)을 제시합니다.
- 이 보고서는 각 부문의 잠재적 매출 기회를 밝히고, 이 시장에서 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 이 보고서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요 인사이트도 제공합니다.
- 이 보고서는 다음과 같은 매개 변수를 기반으로 세계의 선천성 고인슐린혈증 치료제 시장의 주요 기업을 분석합니다. 구체적으로 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적 및 전략 등입니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것으로 기대됩니다.
- 이 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 선천성 고인슐린혈증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 쉽게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 범위
제3장 시장 역학, 규제 및 동향 분석
제4장 세계의 선천성 고인슐린혈증 치료 시장 : 질환 유형별, 2026-2033년
제5장 세계의 선천성 고인슐린혈증 치료 시장 : 약제 유형별, 2026-2033년
제6장 세계의 선천성 고인슐린혈증 치료 시장 : 투여 경로별, 2026-2033년
제7장 세계의 선천성 고인슐린혈증 치료 시장 : 유통 채널별, 2026-2033년
제8장 세계의 선천성 고인슐린혈증 치료 시장 : 지역별, 2026-2033년
제9장 경쟁 구도
제10장 섹션
KSA 26.04.30Congenital Hyperinsulinism Treatment Market is estimated to be valued at USD 158.4 Mn in 2026 and is expected to reach USD 321.6 Mn by 2033, growing at a compound annual growth rate (CAGR) of 8.2% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 158.4 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.20% | 2033 Value Projection: | USD 321.6 Mn |
Congenital hyperinsulinism(CHI) also called as hyperinsulinemic hypoglycemia, a rare endocrine condition that causes low blood glucose levels and occurs mainly in newborn babies, infants and children leading to permanent brain injury and is most frequent cause of severe hypoglycemia. Over secretion of insulin by beta cells in pancreas leads to gene mutation in KATP channel genes (ABCC8 and KCNJ11, HNF4A, HNF1A, HADH, and UCP2 or activating mutations of GLUD1, GCK, and SLC16A1) that cause congenital hyperinsulinism. There is significant risk of permanent brain damage in CHI, hence it is necessary to make a prompt diagnosis and obtain immediate management of the disease to prevent complications such as epilepsy, cerebral palsy and neurodevelopmental deficits. According to the National Organization for Rare Disorders database, approximately 1/25,000 to 1/50,000 HI births occurs in most of the countries including HI develop hypoglycemia during the first month of life. Irritability, sleepiness, excessive hunger, rapid heart rate are common symptoms that occurs while more severe symptoms, such as seizures and coma occur. There are many causes of congential hyperinsulinism based on different forms of the disease for example there are transient forms while some are due to genetic defects and persist for life. Prematurely born babies sometimes, develop hypoglycemia due to excessive insulin secretion. The cause of this inappropriate insulin secretion is still not clear, but it can last a few days to months.
Market Dynamics
Ongoing research for development of novel therapeutic options for the treatment of congenital hyperinsulinismby various key players such as Zealand Pharma A/S, Hanmi Pharm.Co., Ltd., Eli Lilly and Company is anticipated to drive the growth of global congenital hyperinsulinismtreatment market over the forecast period. For instance, in May 2019, Zealand Pharma A/S, a biotechnology company initiated Phase 3 clinical trial of Dasiglucagon. The study aims to assess the efficacy and safety of Dasiglucagon for the treatment of pediatric patients with congenital hyperinsulinism. The study is estimated to be completed by December 2022. Dasiglucagon is a peptide analogue of glucagon consisting 7 amino acid substitutions engineered to eliminate fibril formation as well as peptide aggregation.
Key features of the study
- This report provides an in-depth analysis of the global congenital hyperinsulinism treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global congenital hyperinsulinism treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study are Zealand Pharma A/S, Eli Lilly and Company, Xeris Pharmaceuticals, Inc., Rezolute, Inc., Hanmi Pharm.Co., Ltd., Fresenius Kabi AG, Eiger BioPharmaceuticals., Crinetics Pharmaceuticals, Inc., AmideBio, LLC, Jolly Healthcare, e5 Pharma,LLC, Merck & Co.,Inc., Novo Nordisk A/S, Amphaster Pharmaceuticals,Inc., USV Private Limited, Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global congenital hyperinsulinism treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global congenital hyperinsulinism treatment market
Market Segmentation
- By Disease Type
- KATP-HI
- GDH-HI
- GK-HI
- Other (SCHAD HI,HNF4A/HNF1A, etc.)
- By Drug Type
- Diazoxide
- Octreotide
- Glucagon
- Nifedipine
- Other (Sirolimus, Chlorothiazide, etc.)
- By Route of Administration
- Oral
- Parenteral
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Zealand Pharma A/S
- Eli Lilly and Company
- Xeris Pharmaceuticals, Inc.
- Rezolute, Inc.
- Hanmi Pharm.Co., Ltd.
- Fresenius Kabi AG
- Eiger BioPharmaceuticals.
- Crinetics Pharmaceuticals, Inc.
- AmideBio,LLC
- Jolly Healthcare
- e5 Pharma,LLC
- Merck & Co.,Inc.
- Novo Nordisk A/S
- Amphaster Pharmaceuticals,Inc.
- USV Private Limited
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Disease Type
- Market Snapshot, By Drug Type
- Market Snapshot, By Route of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Recent Developments
- Acquisitions and Partnerships Scenario
- Regulatory Scenario
- Pricing Analysis
- PEST Analysis
4. Global Congenital Hyperinsulinism Treatment Market, By Disease Type, 2026-2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- KATP-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- GDH-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- GK-HI
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Other (SCHAD HI, HNF4A/HNF1A HI, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Congenital Hyperinsulinism Treatment Market, By Drug Type, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Diazoxide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Octreotide
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Glucagon
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Nifedipine
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Other (Sirolimus, Chlorothiazide, etc.)
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Congenital Hyperinsulinism Treatment Market, By Route of Administration, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Parenteral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Congenital Hyperinsulinism Treatment Market, By Distribution Channel, 2026 - 2033, (USD Mn)
- Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021-2033
- Segment Trends
- Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Congenital Hyperinsulinism Treatment Market, By Region, 2026 - 2033, (USD Mn)
- Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2021-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- UK
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type , 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2026 - 2033, (USD Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026-2033, (USD Mn)
- North Africa
- Central Africa
- South Africa
9. Competitive Landscape
- Zealand Pharma A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Xeris Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Rezolute, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Hanmi Pharm.Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Fresenius Kabi AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eiger BioPharmaceuticals.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Crinetics Pharmaceuticals, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AmideBio,LLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Jolly Healthcare
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- e5 Pharma, LLC.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novo Nordisk A/S
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Amphastar Pharmaceuticals.Inc,
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- USV Private Limited.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
10. Section
- Research Methodology
- About Us
